TradersLink
$ATNMOct 15, 2026, 8:31 AM ETAI processed

Actinium to present first‑in‑human Phase 1 data for ATNM‑400 (non‑PSMA Ac‑225 radiotherapy) at EANM

AI Summary

Actinium will orally present early results from the first‑in‑human Phase 1 dose‑escalation trial of ATNM‑400 at EANM 2026, showing Zr‑89 PET theranostic data used to characterize safety, biodistribution and dosimetry to inform Actinium‑225 therapeutic dosing. ATNM‑400 is a non‑PSMA targeted antibody radioconjugate intended to address PSMA‑low/negative and PSMA‑refractory mCRPC, but the company disclosed no specific efficacy or safety outcomes yet and the data are described as early.

Positives

  • Oral presentation at EANM of first‑in‑human Phase 1 theranostic data for ATNM‑400 (raises clinical visibility)
  • Study includes Zr‑89 PET imaging to inform dosimetry for planned Actinium‑225 therapeutic dosing
  • ATNM‑400 targets a non‑PSMA antigen, potentially addressing PSMA‑low/negative and PSMA‑refractory mCRPC populations

Negatives

  • Company provided no specific efficacy or safety results in the announcement
  • Data are early (Phase 1 dose‑escalation), so clinical benefit and regulatory path remain uncertain
  • No patient numbers, endpoints, or dosimetry values were disclosed in the release